## AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

## Listing of the Claims:

1 (currently amended). A method for treating an inflammatory disease inhibiting cell functioning as a target for use in anti-inflammatory therapies and in treating myeloid leukemia in the body of a warm-blooded living being, comprising which comprises administering to said being, in a quantity effective for said treatment, a drug comprising, in a quantity effective for said therapies, a substance that specifically recognizes the extracellular domain of SIRP (anti-SIRP substance) and that inhibits the functioning of macrophages by suppressing their activation by a factor of at least 10 as measure by each of the following macrophage activity tests: (i) the production of nitric oxide (NO), (ii) the production of reactive oxygen species, and (iii) the production of tumor necrosis factor-alpha (TNF-α), said anti-SIRP substance being selected from Fab-fragments of monoclonal antibodies and (bio) chemically modified products of such fragments wherein the intended anti-SIRP activity has been maintained.

Claims 2-7 (canceled).

8 (currently amended). The method as claimed in claim 1, wherein said anti-SIRP substance is:

(i) a Fab fragment of monoclonal antibody ED9, deposited with the ECACC and assigned ECACC No. 95110626, or a (bio) chemically modified product of said fragment that maintains the anti-SIRP activity, or

(ii) a Fab fragment of monoclonal antibody ED17, deposited with the ECACC and assigned ECACC No. 95110627 or a (bio) chemically modified product of said fragment that maintains the anti-SIRP activity a Fab fragment of monoclonal antibody ED9 or ED17, or said modified product thereof.

Claims 9-10 (canceled).

Claims 11-14 (withdrawn).

15 (new). The method of claim 1, in which the inflammatory disease is selected from the group consisting of allergic disease and autoimmune disease.

16 (new). A method for treating myeloid leukemia in a warm-blooded living being, which method comprises administering to said being, in a quantity effective for said treatment, a

composition comprising a substance that specifically recognizes the extracellular domain of SIRP (anti-SIRP substance) and that inhibits the functioning of macrophages by suppressing their activation by a factor of at least 10 as measure by each of the following macrophage activity tests: (i) the production of nitric oxide (NO), (ii) the production of reactive oxygen species, and (iii) the production of tumor necrosis factor-alpha (TNF-α), said anti-SIRP substance selected from Fab-fragments of monoclonal antibodies and (bio) chemically modified products of such fragments wherein the intended anti-SIRP activity has been maintained.

- 17 (new). The method as claimed in claim 16, wherein said anti-SIRP substance is:
- (i) a Fab fragment of monoclonal antibody ED9, deposited with the ECACC and assigned ECACC No. 95110626, or a (bio) chemically modified product of said fragment that maintains the anti-SIRP activity, or
- (ii) a Fab fragment of monoclonal antibody ED17, deposited with the ECACC and assigned ECACC No. 95110627 or a (bio) chemically modified product of said fragment that maintains the anti-SIRP activity.